Insider transactions

EDGAR

EXACT SCIENCES CORPORATION

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 176

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-03-23 Filed 2026-03-23Baranick Brian Officer: EVP, GM, Precision Oncology
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)33,3210—137,195Direct (D) No
F1, F2
  • F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent.
  • F2 At the effective time of the Merger (the Effective Time), each performance based restricted stock unit (PSU) outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the Merger Consideration) in respect of each share of the Issuer's common stock, par value $0.01 per share (Common Stock) subject to such PSU, less any applicable tax withholding.
Open filing 0001193125-26-118765 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Baranick Brian Officer: EVP, GM, Precision Oncology
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)137,195——0Direct (D) No
F3
  • F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Open filing 0001193125-26-118765 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Baranick Brian Officer: EVP, GM, Precision Oncology
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)795——0Indirect (I) Held in 401(k) PlanNo
F3
  • F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Open filing 0001193125-26-118765 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Baranick Brian Officer: EVP, GM, Precision Oncology
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Restricted Stock Units — underlying Common Stock (28,063)
Disposed (D)28,063——0Direct (D) No
F4, F6, F5
  • F4 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock.
  • F6 At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.
  • F5 These RSUs vest in four equal annual installments beginning on February 25, 2027.
Open filing 0001193125-26-118765 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23COWARD D SCOTT Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)52,164——5,398Direct (D) No
F1
  • F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the Effective Time), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (Common Stock), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the Merger Consideration).
Open filing 0001193125-26-118752 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23COWARD D SCOTT Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)5,398——0Direct (D) No
F2
  • F2 At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.
Open filing 0001193125-26-118752 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23COWARD D SCOTT Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)4,694——0Indirect (I) Held in 401(k) PlanNo
F1
  • F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the Effective Time), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (Common Stock), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the Merger Consideration).
Open filing 0001193125-26-118752 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23COWARD D SCOTT Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (4,175) — exercise price 44.37
Disposed (D)4,175——0Direct (D) No
F4, F3
  • F4 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
  • F3 These options became exercisable on February 27, 2022.
Open filing 0001193125-26-118752 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23COWARD D SCOTT Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (10,786) — exercise price 92.62
Disposed (D)10,786——0Direct (D) No
F4, F5
  • F4 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
  • F5 These options became exercisable on February 26, 2023.
Open filing 0001193125-26-118752 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23COWARD D SCOTT Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (12,875) — exercise price 98.18
Disposed (D)12,875——0Direct (D) No
F4, F6
  • F4 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
  • F6 These options became exercisable on February 14, 2024.
Open filing 0001193125-26-118752 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Trigg Leslie Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)3,244——13,925Direct (D) No
F1
  • F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the Effective Time), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (Common Stock), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the Merger Consideration).
Open filing 0001193125-26-118740 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Trigg Leslie Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)13,925——0Direct (D) No
F2
  • F2 At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.
Open filing 0001193125-26-118740 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Herriott James Officer: SVP, General Counsel Sec
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)68,195——0Direct (D) No
F1
  • F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the Effective Time), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (Common Stock), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the Merger Consideration).
Open filing 0001193125-26-118762 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Herriott James Officer: SVP, General Counsel Sec
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)1,762——0Indirect (I) Held in 401(k) PlanNo
F1
  • F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the Effective Time), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (Common Stock), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the Merger Consideration).
Open filing 0001193125-26-118762 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Herriott James Officer: SVP, General Counsel Sec
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (793) — exercise price 92.62
Disposed (D)793——0Direct (D) No
F3, F2
  • F3 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
  • F2 These options became exercisable on February 26, 2023.
Open filing 0001193125-26-118762 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Herriott James Officer: SVP, General Counsel Sec
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (2,861) — exercise price 98.18
Disposed (D)2,861——0Direct (D) No
F3, F4
  • F3 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
  • F4 These options became exercisable on February 14, 2024.
Open filing 0001193125-26-118762 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Herriott James Officer: SVP, General Counsel Sec
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Restricted Stock Units — underlying Common Stock (20,321)
Disposed (D)20,321——0Direct (D) No
F5, F7, F6
  • F5 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock.
  • F7 At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.
  • F6 These RSUs vest in four equal annual installments beginning on February 25, 2027.
Open filing 0001193125-26-118762 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Zanotti Katherine S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)55,361——5,398Direct (D) No
F1
  • F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the Effective Time), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (Common Stock), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the Merger Consideration).
Open filing 0001193125-26-118747 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Zanotti Katherine S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)5,398——0Direct (D) No
F2
  • F2 At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.
Open filing 0001193125-26-118747 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Doyle James Edward Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)52,564——5,398Direct (D) No
F1
  • F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the Effective Time), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (Common Stock), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the Merger Consideration).
Open filing 0001193125-26-118744 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Doyle James Edward Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)5,398——0Direct (D) No
F2
  • F2 At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.
Open filing 0001193125-26-118744 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Condella Sarah Officer: EVP, Human Resources
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)60,3890—191,891Direct (D) No
F1, F2
  • F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent.
  • F2 At the effective time of the Merger (the Effective Time), each performance based restricted stock unit (PSU) outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the Merger Consideration) in respect of each share of the Issuer's common stock, par value $0.01 per share (Common Stock) subject to such PSU, less any applicable tax withholding.
Open filing 0001193125-26-118758 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Condella Sarah Officer: EVP, Human Resources
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)191,891——0Direct (D) No
F3
  • F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Open filing 0001193125-26-118758 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Condella Sarah Officer: EVP, Human Resources
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)6,368——0Indirect (I) Held in 401(k) PlanNo
F3
  • F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Open filing 0001193125-26-118758 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Condella Sarah Officer: EVP, Human Resources
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (21,948) — exercise price 21.68
Disposed (D)21,948——0Direct (D) No
F5, F4
  • F5 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
  • F4 These options became exercisable in full on February 23, 2021.
Open filing 0001193125-26-118758 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Condella Sarah Officer: EVP, Human Resources
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (11,700) — exercise price 44.37
Disposed (D)11,700——0Direct (D) No
F5, F6
  • F5 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
  • F6 These options became exercisable on February 27, 2022.
Open filing 0001193125-26-118758 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Condella Sarah Officer: EVP, Human Resources
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (7,790) — exercise price 92.62
Disposed (D)7,790——0Direct (D) No
F5, F7
  • F5 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
  • F7 These options became exercisable on February 26, 2023.
Open filing 0001193125-26-118758 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Condella Sarah Officer: EVP, Human Resources
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (6,581) — exercise price 98.18
Disposed (D)6,581——0Direct (D) No
F5, F8
  • F5 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
  • F8 These options became exercisable on February 14, 2024.
Open filing 0001193125-26-118758 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Condella Sarah Officer: EVP, Human Resources
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Restricted Stock Units — underlying Common Stock (23,334)
Disposed (D)23,224——0Direct (D) No
F9, F11, F10
  • F9 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock.
  • F11 At the Effective Time, each RSU outstanding as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.
  • F10 These RSUs vest in four equal annual installments beginning on February 25, 2027.
Open filing 0001193125-26-118758 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Barber Michael J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)7,738——5,398Direct (D) No
F1
  • F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the Effective Time), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (Common Stock), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the Merger Consideration).
Open filing 0001193125-26-118742 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Barber Michael J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)5,398——0Direct (D) No
F2
  • F2 At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.
Open filing 0001193125-26-118742 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Barber Michael J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Deferred Stock Units — underlying Common Stock (7,422) — exercise price 0
Disposed (D)7,4220.00
0

Derived: shares × price per share. Exact value 0.00.

0Direct (D) No
F3, F4
  • F3 Represents deferred stock unit award issued pursuant to the Company's non-employee director compensation policy (each a DSU). Each DSU represents a contingent right to receive one share of Exact Sciences Corporation common stock.
  • F4 At the Effective Time, each DSU outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such DSU, less any applicable tax withholding.
Open filing 0001193125-26-118742 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Bloomer Aaron Officer: EVP, Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)89,9110—138,679Direct (D) No
F1, F2
  • F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent.
  • F2 At the effective time of the Merger (the Effective Time), each performance based restricted stock unit (PSU) outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the Merger Consideration) in respect of each share of the Issuer's common stock, par value $0.01 per share (Common Stock) subject to such PSU, less any applicable tax withholding.
Open filing 0001193125-26-118759 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Bloomer Aaron Officer: EVP, Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)138,679——0Direct (D) No
F3
  • F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Open filing 0001193125-26-118759 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Bloomer Aaron Officer: EVP, Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)417——0Indirect (I) Held in 401(k) PlanNo
F3
  • F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Open filing 0001193125-26-118759 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Bloomer Aaron Officer: EVP, Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Restricted Stock Units — underlying Common Stock (4,395)
Disposed (D)4,395——0Direct (D) No
F4, F6, F5
  • F4 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock.
  • F6 At the Effective Time, each RSU granted before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding.
  • F5 These RSUs vest in four equal annual installments beginning on February 27, 2026.
Open filing 0001193125-26-118759 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Bloomer Aaron Officer: EVP, Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Restricted Stock Units — underlying Common Stock (28,063)
Disposed (D)28,063——0Direct (D) No
F4, F7, F8
  • F4 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock.
  • F7 At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.
  • F8 These RSUs vest in four equal annual installments beginning on February 25, 2027.
Open filing 0001193125-26-118759 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Popovits Kimberly J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)6,725——9,656Direct (D) No
F1
  • F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the Effective Time), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share (Common Stock), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the Merger Consideration).
Open filing 0001193125-26-118745 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Popovits Kimberly J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)9,656——0Direct (D) No
F2
  • F2 At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.
Open filing 0001193125-26-118745 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Conroy Kevin T Director · Officer: President and CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)119,3120—1,397,738Direct (D) No
F1, F2
  • F1 On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the Merger Agreement), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the Issuer), Abbott Laboratories, an Illinois corporation (Parent), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer (the Merger), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent.
  • F2 At the effective time of the Merger (the Effective Time), each performance based restricted stock unit (PSU) outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the Merger Consideration) in respect of each share of the Issuer's common stock, par value $0.01 per share (Common Stock) subject to such PSU, less any applicable tax withholding.
Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Conroy Kevin T Director · Officer: President and CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)1,397,738——0Direct (D) No
F3
  • F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Conroy Kevin T Director · Officer: President and CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)29,061——0Indirect (I) Held in 401(k) PlanNo
F3
  • F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Conroy Kevin T Director · Officer: President and CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)46,538——0Indirect (I) Held in Grantor Retained Annuity TrustNo
F3
  • F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Conroy Kevin T Director · Officer: President and CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)86,750——0Indirect (I) Held in Grantor Retained Annuity TrustNo
F3
  • F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Conroy Kevin T Director · Officer: President and CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)117,427——0Indirect (I) Held in Grantor Retained Annuity TrustNo
F3
  • F3 At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Conroy Kevin T Director · Officer: President and CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (235,388) — exercise price 21.68
Disposed (D)235,388——0Direct (D) No
F5, F4
  • F5 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
  • F4 These options became exercisable in full on February 23, 2021.
Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Conroy Kevin T Director · Officer: President and CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (66,047) — exercise price 44.37
Disposed (D)66,047——0Direct (D) No
F5, F8
  • F5 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
  • F8 These options became exercisable on February 27, 2022.
Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Conroy Kevin T Director · Officer: President and CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (34,110) — exercise price 92.62
Disposed (D)34,110——0Direct (D) No
F5, F9
  • F5 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
  • F9 These options became exercisable on February 26, 2023.
Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Conroy Kevin T Director · Officer: President and CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (100,916) — exercise price 98.18
Disposed (D)100,916——0Direct (D) No
F5, F10
  • F5 At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
  • F10 These options became exercisable on February 14, 2024.
Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row
2026-03-23 Filed 2026-03-23Conroy Kevin T Director · Officer: President and CEO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Restricted Stock Units — underlying Common Stock (18,143)
Disposed (D)18,143——0Direct (D) No
F6, F7, F15
  • F6 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock.
  • F7 At the Effective Time, each RSU granted under an Issuer stock plan before November 19, 2025 and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration in respect of each share of Common Stock subject to such RSU, less any applicable tax withholding.
  • F15 These RSUs vest in four equal annual installments beginning on February 28, 2024.
Open filing 0001193125-26-118755 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

Showing 1–32 of 32

House members’ trades in this company, newest report first, as filed
MemberTransaction dateTypeAmountOwnerReport
Hon. Kevin Hern (OK01)2026-03-24Sale$1,001 - $15,000DC2026-04-03
Hon. Josh Gottheimer (NJ05)2024-05-10Sale$1,001 - $15,000JT2024-06-08
Hon. Josh Gottheimer (NJ05)2024-02-01Sale (partial)$1,001 - $15,000JT2024-03-07
Hon. Kevin Hern (OK01)2024-01-02Sale$1,001 - $15,000DC2024-02-11
Hon. Josh Gottheimer (NJ05)2023-11-13Sale (partial)$1,001 - $15,000JT2023-12-08
Hon. Josh Gottheimer (NJ05)2023-10-16Purchase$1,001 - $15,000JT2023-11-11
Hon. Josh Gottheimer (NJ05)2023-09-15Sale (partial)$1,001 - $15,000JT2023-10-15
Hon. Josh Gottheimer (NJ05)2023-05-01Sale (partial)$1,001 - $15,000JT2023-06-11
Hon. Josh Gottheimer (NJ05)2023-01-20Purchase$1,001 - $15,000JT2023-02-17
Hon. Kevin Hern (OK01)2023-01-31Sale$1,001 - $15,000JT2023-02-14
Hon. Kevin Hern (OK01)2022-12-19Sale$50,001 - $100,000JT2023-01-13
Hon. Kevin Hern (OK01)2022-05-16Sale$1,001 - $15,000DC2022-06-14
Hon. Josh Gottheimer (NJ05)2021-06-03Sale (partial)$1,001 - $15,000JT2021-07-15
Hon. Kevin Hern (OK01)2021-05-20Purchase$1,001 - $15,000DC2021-06-15
Hon. Kevin Hern (OK01)2021-05-20Purchase$1,001 - $15,000DC2021-06-15
Hon. Kevin Hern (OK01)2021-05-20Purchase$1,001 - $15,000DC2021-06-15
Hon. Kevin Hern (OK01)2021-05-20Purchase$50,001 - $100,000JT2021-06-15
Hon. Josh Gottheimer (NJ05)2020-11-11Purchase$1,001 - $15,000JT2020-12-09
Hon. Josh Gottheimer (NJ05)2020-10-26Purchase$1,001 - $15,000JT2020-11-05
Hon. Josh Gottheimer (NJ05)2020-09-15Sale (partial)$1,001 - $15,000JT2020-10-13
Hon. Kevin Hern (OK01)2020-07-27Purchase$1,001 - $15,000JT2020-08-15
Hon. Josh Gottheimer (NJ05)2020-06-05Sale (partial)$1,001 - $15,000JT2020-07-09
Hon. Josh Gottheimer (NJ05)2020-06-02Sale (partial)$1,001 - $15,000JT2020-07-09
Hon. Donna Shalala (FL27)2019-06-19Purchase$1,001 - $15,0002020-04-27
Hon. Donna Shalala (FL27)2019-06-24Sale$1,001 - $15,0002020-04-27
Hon. Gilbert Cisneros (CA39)2020-03-16Purchase$1,001 - $15,0002020-04-16
Hon. Josh Gottheimer (NJ05)2020-01-22Purchase$1,001 - $15,000JT2020-02-10
Hon. Josh Gottheimer (NJ05)2020-01-10Purchase$1,001 - $15,000JT2020-02-10
Hon. Josh Gottheimer (NJ05)2019-12-10Sale$1,001 - $15,000JT2020-01-06
Hon. Gilbert Cisneros (CA39)2019-09-16Sale (partial)$1,001 - $15,0002019-10-16
Hon. Josh Gottheimer (NJ05)2019-05-10Purchase$1,001 - $15,000JT2019-06-15
Mr. Lamar Smith (TX21)2014-10-16Purchase$1,001 - $15,0002014-11-12

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 12Open filing 0000102909-26-001288 Dispute this row
Capital World Investors Common Stock0.5968,232.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 3Open filing 0001422849-26-000022 Dispute this row
FMR LLC COMMON STOCK2.95,507,112.2611/28/2025 Filed 2025-12-05SCHEDULE 13G/AAmendment 3Open filing 0000315066-25-002960 Dispute this row
Abigail P. Johnson COMMON STOCK2.95,507,112.2611/28/2025 Filed 2025-12-05SCHEDULE 13G/AAmendment 3Open filing 0000315066-25-002960 Dispute this row
Capital World Investors Common Stock8.516,140,861.0009/30/2025 Filed 2025-11-13SCHEDULE 13G/AAmendment 2Open filing 0001422849-25-000083 Dispute this row
Wellington Management Group LLP Common Stock3.05,747,093.0009/30/2025 Filed 2025-11-12SCHEDULE 13G/AAmendment 5Open filing 0000902219-25-000401 Dispute this row
Wellington Group Holdings LLP Common Stock3.05,747,093.0009/30/2025 Filed 2025-11-12SCHEDULE 13G/AAmendment 5Open filing 0000902219-25-000401 Dispute this row
Wellington Investment Advisors Holdings LLP Common Stock3.05,747,093.0009/30/2025 Filed 2025-11-12SCHEDULE 13G/AAmendment 5Open filing 0000902219-25-000401 Dispute this row
FMR LLC COMMON STOCK9.818,588,183.0608/29/2025 Filed 2025-09-08SCHEDULE 13G/AAmendment 2Open filing 0000315066-25-002265 Dispute this row
Abigail P. Johnson COMMON STOCK9.818,588,183.0608/29/2025 Filed 2025-09-08SCHEDULE 13G/AAmendment 2Open filing 0000315066-25-002265 Dispute this row
BlackRock, Inc. Common Stock4.38,070,49306/30/2025 Filed 2025-07-17SCHEDULE 13G/AAmendment 3Open filing 0002052113-25-003037 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,626,574 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201543,661
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,123

Filings made before the SEC required XML are listed, not extracted.

Back to EXACT SCIENCES CORPORATION